Mounjaro generated $8.7 billion for Lilly in the first quarter of 2026, outperforming Merck's Keytruda, which posted sales of ...

Eli Lilly's Mounjaro has overtaken Keytruda to become the world's top-selling medicine. Its rise highlights booming demand ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s ...

Samsung Bioepis announces positive preliminary Phase 1 data for SB27, proposed biosimilar to keytruda (Pembrolizumab).

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

Merck (NYSE:MRK) delivered its fourth consecutive earnings beat, but shares slipped on the earnings report. With acquisition ...

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities ...

By Deena Beasley and Mariam Sunny April 30 (Reuters) - Merck on Thursday beat first-quarter sales expectations on strong ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda ...

On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic ...